Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
| ▸ | GRM6 | O15303 | 1/20 | 0.39 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CACNB4 | O00305 | 2/20 | 0.39 |
| ▸ | CACNA1A | O00555 | 2/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3820745 | 0.89 | MAPT (0.47) | GCGRMAPTHTTALDH1A1KDM4E | |
| SCHEMBL9753340 | 0.88 | GCGR (0.43) | GCGRMAPTALDH1A1KDM4EHPGD | |
| SCHEMBL3822819 | 0.88 | GCGR (0.43) | GCGRMAPTHTTALDH1A1KDM4E | |
| SCHEMBL5095559 | 0.87 | GCGR (0.43) | GCGRMAPTHTTALDH1A1KDM4E | |
| SCHEMBL5094505 | 0.87 | GCGR (0.47) | GCGRMAPTALDH1A1KDM4EHPGD | |
| SCHEMBL5095533 | 0.86 | GCGR (0.42) | GCGRMAPTHTTALDH1A1KDM4E | |
| SCHEMBL5093104 | 0.86 | MAPT (0.44) | GCGRMAPTALDH1A1KDM4EHPGD | |
| SCHEMBL3819543 | 0.86 | GCGR (0.42) | GCGRMAPTHTTALDH1A1KDM4E | |
| SCHEMBL5101498 | 0.86 | ALDH1A1 (0.44) | GCGRMAPTALDH1A1KDM4EHPGD | |
| SCHEMBL3822321 | 0.85 | GCGR (0.41) | GCGRMAPTALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7317009-B2 | Pyrrolopyridazine derivatives | ASTELLAS PHARMA INC. (JP) | 2008-01-08 | — | — | US | disclosed |
| US-7153854-B2 | Pyrrolopyridazine derivatives | ASTELLAS PHARMA INC. (JP) | 2006-12-26 | — | — | US | disclosed |
| US-20060270678-A1 | Pyrrolopyridazine derivatives | ASTELLAS PHARMA INC. (JP) | 2006-11-30 | — | — | US | disclosed |
| EP-1581535-A1 | PYRROLOPYRIDAZINE DERIVATIVES | Astellas Pharma Inc. (JP) | 2005-10-05 | — | — | EP | disclosed |
| US-20050075342-A1 | Pyrrolopyridazine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-04-07 | — | — | US | disclosed |
| WO-2004063197-A1 | PYRROLOPYRIDAZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-29 | — | — | WO | disclosed |
| WO-1991018903-A1 | PYRROLOPYRIDAZINE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075342-A1 | Pyrrolopyridazine derivatives | PDE4A, PDE5A, PDE12 | GCGR 2019/4885MAPT 2752/4885HTT 3062/4885 |
| US-20060270678-A1 | Pyrrolopyridazine derivatives | PDE4A, PDE5A, PDE12 | GCGR 2019/4885MAPT 2752/4885HTT 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.